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REVIEW
Abstract: The leading treatments for postmenopausal osteoporosis are the nitrogen-containing 
bisphosphonates, which are required long term for optimal beneﬁ  t. Oral bisphosphonates have 
proven efﬁ  cacy in postmenopausal osteoporosis in clinical trials, but in practice the therapeutic 
beneﬁ  ts are often compromised by patients’ low adherence. Nonadherence to bisphosphonate 
therapy negatively impacts outcomes such as fracture rate; fractures are in turn associated with 
decreased quality of life. The most common reason cited by patients for their nonadherence 
is that the strict dosing instructions for bisphosphonates are difﬁ  cult to follow. One aspect of 
bisphosphonate administration that can be changed is dosing frequency and several studies have 
evaluated patient preferences for different dosing schedules. Studies have shown a preference 
for a weekly bisphosphonate regimen versus daily dosing and it has been demonstrated that 
this preference for reduced dosing frequency impacts on adherence. Ibandronate is the ﬁ  rst 
nitrogen-containing oral bisphosphonate for osteoporosis that can be administered in a monthly 
regimen and two robust clinical studies demonstrated a strong patient preference for this monthly 
regimen versus a weekly regimen. It is important that physicians consider patient preference 
when prescribing treatment for osteoporosis to ensure that the disease is effectively managed 
for the long-term beneﬁ  t of the patient.
Keywords: postmenopausal osteoporosis, bisphosphonates, preference, adherence, 
ibandronate
Introduction
Osteoporosis affects one in three postmenopausal women but the nature of this generalized, 
initially asymptomatic, chronic disease means that many patients are unaware that they 
have this disease until they experience their ﬁ  rst fracture. Osteoporosis is characterized 
by low bone mass and structural deterioration of bone tissue, leading to bone fragility 
and an increased susceptibility to fractures (WHO 2003a). Bone loss is the result of an 
imbalance in bone turnover, with bone resorption occurring at a faster rate than new bone 
formation. The resulting reduction in bone mass and accompanying damage to bone 
microarchitecture increases the risk of fracture. The most common form of osteoporosis, 
that experienced by postmenopausal women, results from reduced estrogen production 
following the menopause; by increasing bone resorption, estrogen deﬁ  ciency disrupts 
the ﬁ  ne balance of the bone remodeling cycle. The spine (vertebral fractures), hips, and 
wrists (nonvertebral fractures) are the most common sites of osteoporosis-related bone 
fractures (ie, fractures that are out of proportion to the level of external trauma), although 
osteoporosis-related fractures can occur at almost any skeletal bone site. 
Patients who suffer a vertebral fracture are subsequently at an increased risk 
of further fractures of all types, including hip fractures (Johnell et al 2001). Large 
prospective fracture studies have demonstrated an increased mortality rate following 
vertebral fracture. In the Study of Osteoporotic Fractures (SOF), women with at least 
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one prevalent vertebral fracture experienced a 23% greater 
age-adjusted mortality rate than age-matched controls in 
the general population (Johnell et al 2004). In patients with 
postmenopausal osteoporosis in the Fracture Intervention 
Trial (FIT) (Melton 2000) and the European Prospective 
Osteoporosis Study (EPOS) (Kanis et al 2004), it was dem-
onstrated that the presence of a vertebral fracture increases 
the relative risk of mortality by approximately 60%.
In addition to mortality, vertebral fractures are associated 
with debilitating pain (lasting several weeks or months, with 
chronic pain lasting for many years), kyphosis (curvature 
of the spine, leading to height loss, abdominal protrusion, 
and a hump at the top of the spine), disability, and restricted 
movement (Ross 1997; Center et al 1999; Lips et al 1999; 
Cummings and Melton 2002; Hodgson et al 2003; Jalava et 
al 2003; Lips 2003; Naves et al 2003). There are also psy-
chological effects; patients may experience anxiety about 
their loss of independence, as well as having a fear of falls 
and further fractures. Nonvertebral fractures, especially hip 
fractures, are devastating; around half of the patients who 
experience a hip fracture will never be able to walk again 
without assistance (Johnell 1997) and as many as 30% of 
hip fracture patients require permanent institutional care 
(Lips et al 1999).
Population-based outcome modeling estimates that Cau-
casian women over 50 years of age have a one-in-three risk 
of at least one vertebral fracture and a one-in-ﬁ  ve risk of at 
least one hip fracture in their remaining lifetime (Chrischilles 
et al 1991). The incidence of osteoporosis-related fractures 
increases with age, so as the population ages, the number 
of osteoporosis-related fractures is projected to increase 
dramatically (Cooper et al 1992; Melton et al 1992). Over-
all, 40% of women with postmenopausal osteoporosis will 
suffer one or more fragility fractures during their remaining 
lifetime (Melton et al 1992). In the year 2000, an estimated 
75 million people had osteoporosis in Europe, the US, and 
Japan (Madhok et al 2000). During 2002, the direct impact 
of this disease translated to an estimated treatment cost in the 
US of $17.5 billion (Melton 2003), and in 2003, in the EU, the 
estimated total direct cost of osteoporosis-related fractures 
was  25 billion (IOF 2003). Due to the increasing burden of 
osteoporosis, there is a real need for effective treatments. 
Bisphosphonates for the treatment 
of osteoporosis
The aim of pharmacological intervention in postmenopausal 
osteoporosis is to reduce the frequency of fractures and, 
consequently, reduce the related burden on patients and 
healthcare services and improve patients’ quality of life. 
The leading treatments for postmenopausal osteoporosis are 
the nitrogen-containing bisphosphonates. These antiresorp-
tive agents reduce postmenopausal bone loss by inhibiting 
osteoclast activity and reducing the rate of bone resorption. 
This shifts the balance in favor of bone formation, so that 
bone mass is increased (Russell and Rogers 1999). In numer-
ous robust clinical trials, the nitrogen-containing bisphos-
phonates alendronate, risedronate, and ibandronate have 
consistently demonstrated considerable increases in bone 
mineral density (BMD) of the spine and hip and decreases 
in the biochemical markers of bone turnover together with 
substantial antifracture efﬁ  cacy (Black et al 1996; Cum-
mings et al 1998; Harris et al 1999; Reginster et al 2000; 
Chesnut et al 2004). Additionally, the bisphosphonates are 
the only antiresorptive agents shown in a meta-analysis to 
signiﬁ  cantly reduce the risk of nonvertebral fractures (Cran-
ney et al 2002) and, in a prospective analysis, risedronate 
was shown to reduce the risk of hip fracture (McClung et 
al 2001). All three of these bisphosphonates have favorable 
safety proﬁ  les, which have been shown in clinical studies to 
be similar to placebo. However, long-term treatment with 
bisphosphonates is required for optimal and sustained beneﬁ  t 
and although oral bisphosphonates have proven efﬁ  cacy in 
women with postmenopausal osteoporosis in clinical trials, 
the therapeutic beneﬁ  ts in clinical practice are often com-
promised by patients’ low compliance to, and persistence 
with, their prescribed medication. Compliance describes 
the quality of intake of a given medication and considers the 
extent to which a dosing regimen and its associated instruc-
tions are followed. Compliance can often be quantiﬁ  ed by a 
surrogate measure, the medication possession ratio, which 
is the number of days of available medication divided by the 
number of days of study follow-up. Persistence describes the 
length of time patients continue to take their medication, and 
is deﬁ  ned as the time from treatment initiation to treatment 
completion/discontinuation. Using the PHARMO Record 
Linkage System, which includes drug-dispensing records 
from community pharmacies serving more than 1 million 
community-dwelling patients in the Netherlands, Penning-
van Beest and colleagues (2004) showed that, overall, 1-year 
persistence with bisphosphonate therapy (daily or weekly) 
is low. Among 2124 new bisphosphonate users (alendronate 
daily or weekly, risedronate daily, etidronate daily), only 
43% were persistent at 1 year. As few as 39% of patients 
may persist with weekly bisphosphonates at 1 year (Cowell 
et al 2005) and persistence at 2 years could be as low as 
18%–23% (Harris et al 2005; Siris et al 2005).Clinical Interventions in Aging 2006:1(4) 417
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Impact of poor therapeutic adherence
Adherence is a summary term that is determined by com-
pliance and persistence of medication intake. Adherence 
is thus used to describe the extent and the quality of 
medication intake. Adherence to medication in postmeno-
pausal osteoporosis is in line with the general ﬁ  nding of low 
persistence rates in other chronic diseases. Following an 
inspection of several reviews, the World Health Organiza-
tion estimated that long-term adherence in chronic disease 
averages only 50% (WHO 2003b). In a recent meta-analysis 
of the association between adherence to drug therapy and 
mortality, nonadherent patients with chronic disorders had 
a higher mortality rate than their adherent counterparts 
(Simpson et al 2006). It seems that this is particularly true 
for diseases like postmenopausal osteoporosis that have few 
or no clinical symptoms, as the patient does not experience 
ill effects from the disease or the subsequent beneﬁ  t from 
treatment. 
In the treatment of osteoporosis, nonadherence 
to bisphosphonate therapy negatively impacts upon 
treatment outcomes, for instance poor adherence is as-
sociated with a signiﬁ  cantly higher rate of vertebral and 
nonvertebral fractures (see Figure 1), which are in turn 
associated with a decreased quality of life (Caro et al 
2004; Sebaldt et al 2004; Harris et al 2005; Siris et al 
2005). The antifracture efﬁ  cacy of bisphosphonates has 
been demonstrated in clinical studies with 2–4 years of 
treatment, therefore if fewer than half of patients are ad-
hering to therapy after just 1 year, it is unlikely that the 
same degree of antifracture efﬁ  cacy will be achieved as has 
been shown in clinical trials. Nonadherent bisphosphonate 
use also increases the risk of hospitalization associated 
with osteoporotic fractures (Goettsch et al 2005). Thus, 
as would be expected, nonadherence with bisphosphonate 
therapy correlates with reduced gains in BMD and lower 
reductions in the levels of bone turnover markers (Eastell 
et al 2003; Sebaldt et al 2004). As well as adversely af-
fecting these primary treatment outcomes, nonadherence 
leads to an increased incidence of secondary complica-
tions associated with fractures, such as pain, nosocomial 
infections, and pulmonary thromboembolism, and hence 
to increased healthcare costs.
Understanding the causes of poor 
adherence
Given the impact of nonadherence to therapy on patient 
outcomes and healthcare resources, it is clearly important 
to improve adherence. However, to improve therapeutic ad-
herence it is important to know why patients stop taking, or 
do not take adequate amounts of, their medication. Overall, 
the main reasons patients cite for not continuing to take their 
osteoporosis medication are the stringent dosing schedule, 
adverse events, not feeling that treatment is working, or not 
believing that they have a disease that needs treating (see 
Figure 2) (IOF 2005). The most common of the reasons 
cited above for nonadherence is that patients ﬁ  nd the strict 
dosing instructions for bisphosphonates difﬁ  cult to follow; 
fasting (overnight for at least 6 hours prior to taking the 
medication and 30–60 minutes after administration), and 
posture (staying upright for 30–60 minutes after taking the 
medication) requirements can be inconvenient and often not 
feasible in the daily routine. The strict requirements inter-
fere not only with eating and drinking, but also with taking 
other medications, especially if these need to be taken with 
food. The next most common reason for discontinuation of 
therapy is that despite clinical studies reporting side-effect 
proﬁ  les that are similar to placebo, many patients stop taking 
treatment due to adverse events. The main complaints with 
oral bisphosphonates are upper gastrointestinal irritation, 
dyspepsia, nausea, upper abdominal pain, vomiting, and 
gastroesophageal reﬂ  ux. Finally, as patients often have no 
symptoms until they suffer a fracture, they do not feel that 
treatment is worth taking or do not believe they have a disease 
that needs treatment. This means they may consider the pill 
burden and inconvenience of the dosing requirements to be 
unnecessary. It has been suggested that, compared with other 
chronic diseases, adherence in osteoporosis is compromised 
because measures of therapeutic outcome (such as increases 
in BMD and reductions in the level of biochemical markers 
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Figure 1 Fractures are increased as a result of suboptimal adherence: trend of 
a 33% greater fracture rate in inconsistenta versus consistent users (Sebaldt et al 
2004).
Note: aInconsistent = early discontinuation or self-reported taking of therapy <80% 
of the time over the follow-up interval. Clinical Interventions in Aging 2006:1(4) 418
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of bone turnover) are not readily available, therefore patients 
are unable to monitor their response to medication and thus 
gain feedback regarding the beneﬁ  ts of their medication 
(IOF 2005). 
Many physicians believe that the main reason for patients 
not continuing to take their osteoporosis medication is a lack 
of understanding of the beneﬁ  ts of treatment. However, in 
the IOF adherence survey (IOF 2005), 71% of physicians 
questioned recognized that they did not know why their 
patients were discontinuing treatment. Almost half of the 
physicians surveyed believed that the best way to motivate 
patients to continue on treatment is to talk to them about risks 
and complications, however, the patients surveyed believed 
that it may be better to adopt a more positive approach that 
stresses the beneﬁ  ts of therapy. 
Strategies to overcome 
the problem of nonadherence
On the whole, patients with osteoporosis want an effec-
tive and well-tolerated treatment, however, even with the 
proven efﬁ  cacy and safety proﬁ  les of the bisphosphonates 
from clinical trials, patients still do not remain on treatment. 
Therefore other strategies are needed to improve therapeutic 
adherence. Improved communication between physicians and 
their patients may be one way to help. During the IMPACT 
(Improving the Measurements of Persistence on Actonel 
Treatment) study, patients were given verbal feedback 
regarding their bone turnover marker results (Delmas et al 
2003). The study showed that a signiﬁ  cant improvement in 
persistence was achieved if patients were given a positive 
message regarding their response to treatment. It has also 
been shown that involving patients in treatment decisions 
and matching them with their preferences improves patient 
satisfaction, adherence, perception of health, and outcomes 
(Lopes et al 2001; Janz et al 2004; Jahng et al 2005; Lin et 
al 2005). With regards to pharmacological intervention, pa-
tients have identiﬁ  ed key product attributes as being efﬁ  cacy, 
side effects, formulation, costs, drug interactions, dosing 
procedure, and dosing frequency. For the bisphosphonates, 
it is acknowledged that most of these attributes cannot be 
altered. However, one attribute that can be changed is the 
dosing frequency. Several studies have evaluated patient 
preferences for different dosing schedules and the impact 
this has had on therapeutic adherence.
Patient preference for an increased dos-
ing interval: weekly dosing
The registration studies, which showed antifracture ef-
ﬁ  cacy for the oral bisphosphonates, were all conducted 
using a daily regimen (Black et al 1996; Cummings et al 
1998; Harris et al 1999; Reginster et al 2000; Chesnut et al 
2004). The comparable antifracture efﬁ  cacy of weekly oral 
bisphosphonate regimens of alendronate and risedronate with 
their respective daily regimens has been inferred based on 
equivalent increases in BMD (a validated surrogate marker 
for antifracture efﬁ  cacy), and decreases in bone turnover 
markers (Schnitzer et al 2000; Brown et al 2002). The weekly 
regimens of alendronate and risedronate are both licensed 
and are widely accepted as being at least as effective as 
the daily regimens with the added convenience of only one 
tablet a week. In several studies evaluating bisphosphonate 
regimen preference (using alendronate or risedronate), there 
was a strong preference for a weekly regimen versus daily 
dosing (see Table 1). The weekly regimen was considered 
by the patients to be more convenient, would allow them to 
achieve better long-term compliance, and was the regimen 
that most said they would be willing to take for an extended 
period of time, ie, would improve their adherence (Simon et 
al 2002; Baroutsou et al 2004; Cramer et al 2004; Kendler et 
al 2004; Recker et al 2004; Bartl et al 2006).
It has been demonstrated that patient preference for 
reduced bisphosphonate dosing frequency has impacted 
on therapeutic adherence. Studies that compared daily and 
weekly regimens found that a weekly regimen of alendronate 
or risedronate signiﬁ  cantly increased rates of compliance 
versus a daily treatment (see Table 2) (Cramer et al 2005; 
Recker et al 2005; Bartl et al 2006). Patients receiving daily 
bisphosphonates ﬁ  lled prescriptions for only 33%–58% 
of their prescribed medication, while patients receiv-
ing a weekly regimen obtained more of their prescribed 
Figure 2 Reasons given by patients for not adhering to bisphosphonate therapy 
for osteoporosis (IOF 2005).
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medication (46%–69%). Around half (41%–55%) of patients 
receiving a weekly regimen were highly compliant (at least 
80% of prescribed medication taken) compared with only 
23%–40% of patients taking a daily treatment. Preference 
for less frequently dosed bisphosphonate regimens also 
translates to improved therapeutic persistence (see Table 
3). Analyses of a number of health databases of patients in 
the clinical setting show that 1-year persistence increases 
with weekly bisphosphonate dosing regimens by 12%–29% 
versus daily dosing (Ettinger et al 2004; Penning-van Beest 
et al 2004; Sunyecz et al 2004; Cramer et al 2005; Bartl et 
al 2006). However, fewer than half of patients receiving a 
weekly regimen persist with their therapy for 12 months 
so, even though adherence has been improved with weekly 
regimens versus daily, it is still suboptimal. Adherence, 
and therefore potentially quality of life, may be improved 
by further increasing the dosing interval, for instance from 
daily or weekly to monthly (Simon et al 2005). 
Increasing the dosing interval fur-
ther: monthly dosing
Ibandronate is the ﬁ  rst nitrogen-containing oral bisphospho-
nate for osteoporosis that can be administered in a monthly 
regimen, and it is anticipated that this regimen may have a 
positive impact on adherence, and therefore ultimately on 
fracture prevention. Similarly to the other currently licensed 
oral bisphosphonates for postmenopausal osteoporosis, daily 
ibandronate has well documented clinical efﬁ  cacy (Riis et al 
2001; Chesnut et al 2004; Miller et al 2005). When given in 
an intermittent schedule (dosing interval >2 months), oral 
ibandronate also provides signiﬁ  cant vertebral antifracture 
efﬁ  cacy (relative risk reduction 50%, p=0.0006 versus pla-
cebo), which represents the ﬁ  rst prospective demonstration 
of antifracture efﬁ  cacy with a bisphosphonate administered 
Table 1 Patients’ preference for weekly versus daily dosing of bisphosphonates
Study   Dose  regimens   Outcome 
Multicenter randomized crossover (n=287)    4 weeks of daily alendronate   86.4%  preferred  weekly 
(Simon et al 2002)    1 week washout    89.0% thought weekly convenient 
  4 weeks of weekly alendronate    87.5% expected weekly to improve compliance 
Multicenter randomized crossover observational   4 weeks of daily alendronate   84.0%  preferred  weekly 
(n=406)   (Kendler et al 2004)   1  week  washout    87.0% thought weekly convenient 
  4 weeks of weekly alendronate    84.0% would receive weekly long term 
Multicenter observational switchover (n=2997)    6 months of daily calcitonin, raloxifene  99.5% preferred weekly 
(Baroutsou et al 2004)   or  bisphosphonate    99.8% thought weekly convenient 
  24 weeks of weekly alendronate    99.8% willing to use weekly long term 
Table 2 Studies of compliance with weekly compared with daily bisphosphonate regimens
Study    Dose regimens (n)   MPR  (%)   MPR  ≥80% (%) 
IHCIS database (1997–2002)  Daily alendronate or risedronate (2010)   58     40   
  (Cramer et al 2005)    Weekly alendronate (731)   69  (p<0.0001)   55  (p<0.0001) 
IMS Mediplus    Daily alendronate (144)   38   19 
(Bartl et al 2006)    Weekly alendronate (144)   51   31  (p<0.05) 
NDCHealth retrospective database    Daily alendronate or risedronate (33767)   54     ~33   
(Recker et al 2004)    Weekly alendronate or   65 (p<0.001)   ~45  (p<0.001) 
 risedronate  (177552)    
Abbreviations: MPR, medication possession ratio.
Table 3 Studies of persistence with weekly compared with daily bisphosphonate regimens
    Study       Dose regimens (n)    Days to treatment  Days of treatment 
   discontinuation   duration 
IHCIS database (1997–2002)    Daily alendronate or risedronate (2010)   185     134   
(Cramer et al 2005)    Weekly alendronate (731)   227   269 
IMS Mediplus  (Bartl et al 2006)    Daily alendronate (144)   153   – 
  Weekly alendronate (144)   212   – 
NDCHealth retrospective database    Daily alendronate or  –     198   
(Ettinger et al 2004; Sunyecz et al 2004)   risedronate  (33767) 
  Weekly alendronate or risedronate   –   238 
 (177552)    Clinical Interventions in Aging 2006:1(4) 420
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less frequently than daily (Chesnut et al 2004). It is important 
to note that when the treatment-free interval is increased, the 
cumulative bisphosphonate dose must also be increased. Daily 
and intermittent ibandronate of the same cumulative dose pro-
vided comparable efﬁ  cacy, however, similar to studies of daily 
and weekly bisphosphonates, a small, yet consistent, efﬁ  cacy 
advantage was seen in favor of the daily regimen. Hence, in 
studies to evaluate a monthly regimen, oral doses beyond the 
cumulative monthly dose provided by the daily regimen were 
explored to compensate for the greater between-dose interval. 
As with the weekly regimens of alendronate and risedronate, a 
comparable vertebral antifracture proﬁ  le for the monthly regi-
men of ibandronate with the daily regimen is inferred based on 
increases in BMD at all bone sites that are at least equivalent 
to those observed with the daily regimen (Miller et al 2005; 
Reginster et al 2006). Trial data from the MOBILE (Monthly 
Oral Ibandronate In Ladies) study showed that monthly iban-
dronate increased lumbar spine BMD and decreased markers 
of bone turnover and that the 150 mg monthly regimen was 
superior to the daily regimen (Miller et al 2005; Reginster et 
al 2006). After both 1 and 2 years of the study, the monthly 
regimen showed a good tolerability proﬁ  le, similar to that of 
the daily regimen (Chesnut et al 2004). 
Patient preference for a monthly 
regimen
Two robust clinical studies with almost 700 patients using 
patient surveys have demonstrated a strong patient prefer-
ence for a monthly versus a weekly oral bisphosphonate 
regimen (Emkey et al 2005; Hadji et al 2006). The BALTO 
(Bonviva ALendronate Trial in Osteoporosis) studies evalu-
ated patients’ preference for monthly oral ibandronate or 
weekly oral alendronate. BALTO I (Emkey et al 2005) and 
BALTO II (Hadji et al 2006) comprised two separate stud-
ies of identical design; both were 6-month, randomized, 
multicenter, two-sequence, open-label, cross-over studies 
conducted in bisphosphonate-naïve or -lapsed women with 
postmenopausal osteoporosis as determined by the treating 
physician. BALTO I (n=342) was a US only study, whereas 
BALTO II (n=350) included centers in the USA and Europe. 
Postmenopausal women were randomized to receive either 
monthly oral ibandronate (150 mg) for 3 months followed 
by weekly oral alendronate (70 mg) for 12 weeks, or weekly 
oral alendronate (70 mg) for 12 weeks followed by monthly 
oral ibandronate (150 mg) for 3 months. All patients were 
informed that both drugs are indicated for the treatment of 
osteoporosis. Patient preference and opinions on convenience 
were assessed using a subject-completed questionnaire.
In BALTO I (Emkey et al 2005), of those women who 
expressed a preference (92.6% of 298 participants), the ma-
jority (71.4%) preferred the monthly ibandronate regimen to 
the weekly alendronate regimen (p<0.0001; see Figure 3). 
Similarly, in those patients expressing an opinion on conven-
ience, the monthly regimen of ibandronate was assessed as 
being more convenient for patients than the weekly regimen 
of alendronate (74.6% vs 25.4%, respectively; p<0.0001; see 
Figure 4). More women reported that the monthly regimen 
would be easier to follow for a long time (61% vs 25%), was 
better suited to their lifestyle (55% vs 21%), and was easier 
to tolerate (17% vs 4%) than the weekly regimen. In addition, 
patients indicated that there was a greater likelihood of long-
term adherence and better tolerance of adverse events with 
the monthly regimen than the weekly regimen. The ﬁ  ndings 
from BALTO I were conﬁ  rmed by BALTO II. In BALTO 
II (Hadji et al 2006), of those patients expressing a prefer-
ence (93.1%), the majority (70.6%) preferred the monthly 
ibandronate regimen to the weekly alendronate regimen (see 
Figure 3). Again the difference in preference rate between 
weekly alendronate and monthly ibandronate was statisti-
cally signiﬁ  cant (p<0.0001). Of the patients expressing an 
opinion on convenience, three-quarters found the monthly 
regimen more convenient than the weekly regimen (76.6% 
vs 23.4%, respectively; see Figure 4). As in BALTO I, the 
most common reasons for preferring the monthly ibandronate 
regimen were ease of long-term adherence (81.5%) and better 
ﬁ  t to lifestyle (75.4%). 
Patient preference for a medication may encourage thera-
peutic adherence, but further studies are needed to determine 
how well preference and convenience translate into prolonged 
adherence. The UK PERsistence Study of Ibandronate verSus 
alendronaTe (PERSIST) is the ﬁ  rst trial to investigate persist-
Figure 3 The majority of patients expressing a preference prefer monthly 
bisphosphonate treatment to weekly (Emkey et al 2005; Hadji et al 2006).
Note: Modiﬁ  ed intent-to-treat populations = 298 (BALTO I), 321 (BALTO II); 
aPreference rate for monthly was signiﬁ  cant in both studies (p<0.0001).
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ence with 6 months of a monthly bisphosphonate regimen 
versus a weekly bisphosphonate regimen. Patients were 
randomized to receive either a monthly ibandronate regimen 
(plus a patient support program) or a weekly alendronate 
regimen (Cooper et al 2006). A patient support program is 
available to all patients who are prescribed monthly iban-
dronate in the UK, however, there is no equivalent support 
program available to patients who are prescribed weekly 
alendronate. Therefore, to reﬂ  ect current UK practice, only 
patients randomized to the ibandronate arm were enrolled 
into the program. The 6-month data show that compared 
with alendronate there was a 47% relative improvement in 
the proportion of patients persisting with treatment in the 
ibandronate/patient support program group. This compares 
well with the reported relative improvements in 1-year 
persistence of 12%–29% with weekly versus daily dosing 
(Ettinger et al 2004; Penning-van Beest et al 2004; Sunyecz 
et al 2004; Cramer et al 2005; Bartl et al 2006). Secondary 
endpoints, ie, proportion of patients remaining on treatment 
at study end and proportion of patients discontinuing from the 
study, were also in favor of the monthly regimen. The data 
from the UK PERSIST study suggest that this less frequent 
dosing schedule may provide improved adherence.
Conclusions
To achieve maximum treatment beneﬁ  ts for patients with 
osteoporosis, it is important that physicians discuss all 
options with their patients before a treatment choice is made. 
It has been shown that the majority of patients prefer weekly 
to daily therapy, although adherence with weekly regimens 
remains suboptimal. As adherence with daily or weekly 
bisphosphonates is suboptimal, patients and physicians feel 
there is a need for bisphosphonates with extended dosing 
intervals. Given the reported strong patient preference for 
a monthly regimen, and the impact of patient preference on 
adherence, it is anticipated that monthly ibandronate will 
offer patients an alternative convenient regimen that may 
improve adherence over weekly regimens and thereby en-
hance outcomes. The nitrogen-containing bisphosphonates 
are effective therapies for osteoporosis, but if patients are 
more likely to adhere to a monthly regimen than a daily or 
weekly regimen, then this may be the treatment of choice. An 
effective bisphosphonate that combines a good tolerability 
proﬁ  le with a convenient dosing regimen would be beneﬁ  cial 
for patients and it is important that physicians consider patient 
preference when prescribing the appropriate treatment for 
osteoporosis to ensure that the disease is effectively managed 
for the long-term beneﬁ  t of the patient.
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